NovoCure (NVCR) said Thursday that the US Food and Drug Administration approved its new Head Flexible Electrode transducer arrays for use with Optune Gio, a wearable device for treating glioblastoma multiforme brain cancer in adults.
The company said the redesigned arrays, made with flexible polymer materials, are thinner and lighter than previous models.
Novocure said it plans to transition US users to the upgraded arrays through the first half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments